115 - Microbiome Therapeutics: Leaving the Bench and Arriving at the Bedside

Friday, October 13, 2023

10:30 AM – 11:45 AM US ET

Location: 205 ABC

All relevant financial disclosures have been mitigated.

Moderator(s)

A. Krishna Rao, MD, MS

Associate Professor
University of Michigan
Ann Arbor, MI, United States
Susy Hota, MD MSc

ID Division Head, IPAC Medical Director
University Health Network
Toronto, ON, Canada

Faculty(s)

Vincent Young, MD/PhD (he/him/his)

William Henry Fitzbutler Collegiate Professor
Internal Medicine
University of Michigan Medical School
Ann Arbor, MI, United States

Slides
Michael Woodworth, MD, MSc

Assistant Professor
Department of Medicine
Emory University
Atlanta, GA, United States

Slides
Jennie H. Kwon, DO;MSCI

Associate Professor
Washington University School of Medicine
Saint Louis, MO, United States

Disclosure(s):

A. Krishna Rao, MD, MS: Merck and Company, Inc.: Grant/Research Support (Terminated); Rebiotix Inc.: Advisor/Consultant (Terminated); Seres Therapeutics Inc: Advisor/Consultant (Ongoing); Summit Therapeutics: Advisor/Consultant (Ongoing)

Susy S. Hota, MD MSc: No financial relationships to disclose

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-23-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the history of the development of microbiome therapeutics for the treatment of rCDI and status of efforts for other infectious and non-infectious diseases;
describe the first-ever FDA approval of a human fecal microbiota-derived product for rCDI and review the other microbiome therapies for rCDI in development;
explain the future of FDA approval of microbiome therapeutics from a regulatory and clinical perspective

Presentations:

10:30 AM – 10:55 AM US ET

The Microbiome in C. difficile Infection: Basic Principles and the Development of Microbiome Therapeutics
Speaker: Vincent B. Young, MD/PhD (he/him/his) – University of Michigan Medical School
10:55 AM – 11:20 AM US ET

The Commercial Development of Human Derived Intestinal Microbiota for Prevention of Recurrent C. difficile Infection
Speaker: Michael H. Woodworth, MD, MSc – Emory University
11:20 AM – 11:45 AM US ET

Current and Future Development of Microbiome Therapeutics for Recurrent C. difficile Infection
Speaker: Jennie H. Kwon, DO;MSCI – Washington University School of Medicine